{"entity":{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","aka":[],"tldr":"Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib.","summary":"Suresh S. Ramalingam is Executive Director of Winship Cancer Institute of Emory University, Georgia's NCI-designated comprehensive cancer centre. A thoracic medical oncologist, he was a principal investigator of the FLAURA trial establishing osimertinib as first-line therapy for EGFR-mutated non-small cell lung cancer, and has led numerous national lung cancer trials through ECOG-ACRIN.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramalingam+SS%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","targeted therapy"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["emory-winship"],"pathways":[],"terms":[],"trials":["flaura2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director","institutionId":"emory-winship","specialisms":["Lung cancer","Thoracic medical oncology","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramalingam+SS%5BAuthor%5D"}],"papers":[{"title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa1913662","doi":"10.1056/NEJMoa1913662"}],"orcid":"0000-0002-0757-3106"},"route":"/people/suresh-ramalingam/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"institution":[{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/"}],"trial":[{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/"},{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/"}],"paper":[{"id":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","kind":"paper","name":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","route":"/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/"}]}}